论文部分内容阅读
目的探讨稳心颗粒联合美托洛尔治疗冠状动脉粥样硬化性心脏病合并心律失常患者的临床效果。方法选取2013年1月至2014年2月在海城市腾鳌镇中心卫生院就诊并接受治疗的冠状动脉粥样硬化性心脏病合并心律失常患者128例为研究对象,按随机数字表法分为观察组和对照组,每组64例。对照组患者均给予美托洛尔缓释片单独治疗,观察组加用稳心颗粒联合治疗,比较两组患者的治疗效果、心电图改善情况及不良反应发生情况。结果观察组患者的症状治疗有效率为96.9%,高于对照组的78.1%,差异有统计学意义(P<0.05)。观察组患者的心电图改善有效率为96.9%,明显高于对照组的81.3%,差异有统计学意义(P<0.05)。观察组患者的不良反应发生率为7.8%,低于对照组的23.4%,差异有统计学意义(P<0.05)。结论稳心颗粒联合美托洛尔治疗冠状动脉粥样硬化性心脏病合并心律失常患者效果显著,在改善心电图检测结果的同时提高患者的症状治疗效果,安全性更高。
Objective To investigate the clinical effect of Wenxin granule combined with metoprolol in the treatment of coronary atherosclerotic heart disease with arrhythmia. Methods From January 2013 to February 2014, 128 patients with coronary atherosclerotic heart disease complicated with cardiac arrhythmia treated in Teng’ao Town Center Hospital of Haicheng City were selected as the research object and divided into two groups according to random number table Observation group and control group, 64 cases in each group. Patients in the control group were given metoprolol sustained-release tablets alone, the observation group plus Wenxin granules combined treatment, the treatment effect of two groups were compared, the improvement of ECG and the occurrence of adverse reactions. Results The effective rate of symptom treatment in observation group was 96.9%, which was higher than that in control group (78.1%), the difference was statistically significant (P <0.05). The improvement rate of ECG in the observation group was 96.9%, which was significantly higher than that in the control group (81.3%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 7.8%, which was lower than that in the control group (23.4%), the difference was statistically significant (P <0.05). Conclusion Wenxin granule combined with Metoprolol is effective in treating patients with coronary atherosclerotic heart disease and arrhythmia. It improves the results of electrocardiogram test and improves the therapeutic effect of the symptoms of the patients, and is more safe.